Value through Innovation27 July 2016

Clinical Study Results

  • BIWB 2 - Melanoma
    Clinical Study Number 1155.2
    Study Indication Melanoma
    Product BIWB 2
    Generic Name BIWB 2
    Lab Code
    Clinical Phase I
    Study Title

    An open-label, multicenter, controlled, combined parallel group anddose-escalation (0, 0.12, 1.2, 12.0 11 mcg IL-2/10 8 cells/24 hours) study, to evaluate the safety and tolerability of an allogeneic tumor vaccine BIWB 2 containing melanoma cells transfected with the human IL-2 gene in patients with advanced malignant melanoma

    Study Document Trial synopsis 1155.2_CO english

Clinical Trial Registry and structured study results. Find here protocol information for all clinical study types.

European Trial Register of EU studies.